In today’s recent session, 0.44 million shares of the Mereo Biopharma Group Plc ADR (NASDAQ:MREO) have been traded, and its beta is 0.51. Most recently the company’s share price was $2.30, and it changed around -$0.03 or -1.31% from the last close, which brings the market valuation of the company to $356.75M. MREO at last check was trading at a discount to its 52-week high of $5.02, offering almost -118.26% off that amount. The share price’s 52-week low was $1.58, which indicates that the recent value has risen by an impressive 31.3% since then.
Mereo Biopharma Group Plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.11. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended MREO as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Instantly MREO has been showing red trend so far today with a performance of -1.31% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.75 on recent trading dayincreased the stock’s daily price by 16.36%. The company’s shares are currently down -34.30% year-to-date, but still down -11.22% over the last five days. On the other hand, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) is 25.65% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $7.5, which translates to bulls needing to increase their stock price by 69.33% from its current value. Analyst projections state that MREO is forecast to be at a low of $4 and a high of $8.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 34.82%. Mereo Biopharma Group Plc ADR earnings are expected to increase by 26.19% in 2025, but the outlook is positive 17.79% per year for the next five years.
MREO Dividends
Mereo Biopharma Group Plc ADR’s next quarterly earnings report is expected to be released in June.
ADAGE CAPITAL PARTNERS GP, L.L.C., with 1.6566% or 11.79 million shares worth $42.45 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund and Tema ETF Trust-Tema GLP-1, Obesity & Cardiometabolic ETF were the top two Mutual Funds as of Mar 31, 2025 . The former held 759.1 shares worth $1.75 million, making up 0.48% of all outstanding shares. On the other hand, Tema ETF Trust-Tema GLP-1, Obesity & Cardiometabolic ETF held roughly 267.46 shares worth around $0.62 million, which represents about 0.17% of the total shares outstanding.
